-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on March 24 Recently, Hebei Renhe Yikang Pharmaceutical entered the administrative examination and approval stage with the imitation of 3 types of sodium valproate injection, which is expected to be approved in the near future and won the first imitation in China.
Sodium valproate is the leading product in the domestic antiepileptic drug market.
According to data from Meinenet, the sales of terminal sodium valproate in China's public medical institutions exceeded 2 billion yuan in 2019, and injections accounted for 64.
56% of the market share.
Sodium valproate is the leading product in the domestic antiepileptic drug market.
According to data from Meinenet, the sales of terminal sodium valproate in China's public medical institutions exceeded 2 billion yuan in 2019, and injections accounted for 64.
56% of the market share.
Sodium valproate is a nitrogen-free broad-spectrum antiepileptic drug, which can competitively inhibit Y-aminobutyric acid transaminase and increase the concentration of Y-aminobutyric acid to achieve anticonvulsant effects.
Localized grand mal, grand mal and mixed epilepsy are all effective, and it is mostly used clinically for various epilepsy where other antiepileptic drugs are ineffective.
Localized grand mal, grand mal and mixed epilepsy are all effective, and it is mostly used clinically for various epilepsy where other antiepileptic drugs are ineffective.
Sales of terminal sodium valproate in China's public medical institutions
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Sodium valproate is the leading product in the domestic antiepileptic drug market, and its marketed dosage forms include injections, sustained-release tablets, ordinary tablets and solutions.
According to data from Menet.
com, in 2019, the sales of terminal sodium valproate in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 2 billion yuan, and injections accounted for 64.
56% of the market share.
.
According to data from Menet.
com, in 2019, the sales of terminal sodium valproate in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 2 billion yuan, and injections accounted for 64.
56% of the market share.
.
Market application status of sodium valproate injection
Source: One-click search on Mi Nei.
com
com
Currently, only the domestic market sales of injectable sodium valproate sodium valproate injection products, manufacturers, including Sanofi, Shenyang Pharmaceutical Malaysia and four-Chuankeruide pharmaceutical and other three companies .
Sodium valproate injection has not yet been approved for listing.
Fuan Pharmaceutical, Xi'an Yuanda Detian Pharmaceutical, Hebei Renheyikang Pharmaceutical, and Sichuan Creed Pharmaceuticals use imitations of sodium valproate injection.
3 types of production.
Sodium valproate injection has not yet been approved for listing.
Fuan Pharmaceutical, Xi'an Yuanda Detian Pharmaceutical, Hebei Renheyikang Pharmaceutical, and Sichuan Creed Pharmaceuticals use imitations of sodium valproate injection.
3 types of production.
Hebei Renhe Yikang Pharmaceutical's registration status for this product has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and won the first domestic imitation.
If it is successfully approved, it will be deemed to have been reviewed and won the first domestic imitation.
Source: Minet database
Medical Network News on March 24 Recently, Hebei Renhe Yikang Pharmaceutical entered the administrative examination and approval stage with the imitation of 3 types of sodium valproate injection, which is expected to be approved in the near future and won the first imitation in China.
Sodium valproate is the leading product in the domestic antiepileptic drug market.
According to data from Meinenet, the sales of terminal sodium valproate in China's public medical institutions exceeded 2 billion yuan in 2019, and injections accounted for 64.
56% of the market share.
Sodium valproate is the leading product in the domestic antiepileptic drug market.
According to data from Meinenet, the sales of terminal sodium valproate in China's public medical institutions exceeded 2 billion yuan in 2019, and injections accounted for 64.
56% of the market share.
Sodium valproate is a nitrogen-free broad-spectrum antiepileptic drug, which can competitively inhibit Y-aminobutyric acid transaminase and increase the concentration of Y-aminobutyric acid to achieve anticonvulsant effects.
Localized grand mal, grand mal and mixed epilepsy are all effective, and it is mostly used clinically for various epilepsy where other antiepileptic drugs are ineffective.
Localized grand mal, grand mal and mixed epilepsy are all effective, and it is mostly used clinically for various epilepsy where other antiepileptic drugs are ineffective.
Sales of terminal sodium valproate in China's public medical institutions
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Sodium valproate is the leading product in the domestic antiepileptic drug market, and its marketed dosage forms include injections, sustained-release tablets, ordinary tablets and solutions.
According to data from Menet.
com, in 2019, the sales of terminal sodium valproate in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 2 billion yuan, and injections accounted for 64.
56% of the market share.
.
According to data from Menet.
com, in 2019, the sales of terminal sodium valproate in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 2 billion yuan, and injections accounted for 64.
56% of the market share.
.
Market application status of sodium valproate injection
Source: One-click search on Mi Nei.
com
com
Currently, only the domestic market sales of injectable sodium valproate sodium valproate injection products, manufacturers, including Sanofi, Shenyang Pharmaceutical Malaysia and four-Chuankeruide pharmaceutical and other three companies .
Sodium valproate injection has not yet been approved for listing.
Fuan Pharmaceutical, Xi'an Yuanda Detian Pharmaceutical, Hebei Renheyikang Pharmaceutical, and Sichuan Creed Pharmaceuticals use imitations of sodium valproate injection.
3 types of production.
Sodium valproate injection has not yet been approved for listing.
Fuan Pharmaceutical, Xi'an Yuanda Detian Pharmaceutical, Hebei Renheyikang Pharmaceutical, and Sichuan Creed Pharmaceuticals use imitations of sodium valproate injection.
3 types of production.
Hebei Renhe Yikang Pharmaceutical's registration status for this product has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and won the first domestic imitation.
If it is successfully approved, it will be deemed to have been reviewed and won the first domestic imitation.
Source: Minet database
Medical Network News on March 24 Recently, Hebei Renhe Yikang Pharmaceutical entered the administrative examination and approval stage with the imitation of 3 types of sodium valproate injection, which is expected to be approved in the near future and won the first imitation in China.
Sodium valproate is the leading product in the domestic antiepileptic drug market.
According to data from Meinenet, the sales of terminal sodium valproate in China's public medical institutions exceeded 2 billion yuan in 2019, and injections accounted for 64.
56% of the market share.
Sodium valproate is the leading product in the domestic antiepileptic drug market.
According to data from Meinenet, the sales of terminal sodium valproate in China's public medical institutions exceeded 2 billion yuan in 2019, and injections accounted for 64.
56% of the market share.
Sodium valproate is a nitrogen-free broad-spectrum antiepileptic drug, which can competitively inhibit Y-aminobutyric acid transaminase and increase the concentration of Y-aminobutyric acid to achieve anticonvulsant effects.
Localized grand mal, grand mal and mixed epilepsy are all effective, and it is mostly used clinically for various epilepsy where other antiepileptic drugs are ineffective.
Localized grand mal, grand mal and mixed epilepsy are all effective, and it is mostly used clinically for various epilepsy where other antiepileptic drugs are ineffective.
Sales of terminal sodium valproate in China's public medical institutions
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Sodium valproate is the leading product in the domestic antiepileptic drug market, and its marketed dosage forms include injections, sustained-release tablets, ordinary tablets and solutions.
According to data from Menet.
com, in 2019, the sales of terminal sodium valproate in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 2 billion yuan, and injections accounted for 64.
56% of the market share.
.
Hospital hospital hospitalAccording to data from Menet.
com, in 2019, the sales of terminal sodium valproate in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 2 billion yuan, and injections accounted for 64.
56% of the market share.
.
Market application status of sodium valproate injection
Source: One-click search on Mi Nei.
com
com
Currently, only the domestic market sales of injectable sodium valproate sodium valproate injection products, manufacturers, including Sanofi, Shenyang Pharmaceutical Malaysia and four-Chuankeruide pharmaceutical and other three companies .
Sodium valproate injection has not yet been approved for listing.
Fuan Pharmaceutical, Xi'an Yuanda Detian Pharmaceutical, Hebei Renheyikang Pharmaceutical, and Sichuan Creed Pharmaceuticals use imitations of sodium valproate injection.
3 types of production.
Enterprise business enterpriseSodium valproate injection has not yet been approved for listing.
Fuan Pharmaceutical, Xi'an Yuanda Detian Pharmaceutical, Hebei Renheyikang Pharmaceutical, and Sichuan Creed Pharmaceuticals use imitations of sodium valproate injection.
3 types of production.
Hebei Renhe Yikang Pharmaceutical's registration status for this product has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and won the first domestic imitation.
If it is successfully approved, it will be deemed to have been reviewed and won the first domestic imitation.
Source: Minet database
